Jones Day San Diego, CA Document Search Results (22)
Show: results per page
|The House Judiciary Committee Approves the Senate's Version of the Defend Trade Secrets Act|
Kenneth S. (Ken) Canfield, Douglas L. (Doug) Clark, Randy Kay, Christopher M. (Chris) Morrison, Kelsey I. Nix; Jones Day;
May 10, 2016, previously published on April 2016Legislation for the nation's first federal civil trade secret protection statute has come closer to enactment into law, with the House Judiciary Committee's approval of the bill on April 20, 2016.
|Department of Justice FCPA Pilot Program Outlines Incentives for Corporate Self-Disclosure and Cooperation: What's New and Will It Matter?|
Theodore T. (Ted) Chung, Richard H. (Rick) Deane, Karen P. Hewitt, Henry Klehm, Hank Bond Walther; Jones Day;
May 10, 2016, previously published on April 2016On April 5, the U.S. Department of Justice ("DOJ") announced a one-year "FCPA Enforcement Pilot Program" to encourage voluntary self-disclosure, cooperation, and remediation (the "Pilot Program"). This effort is designed to boost enforcement by further incentivizing...
|Federal Circuit Upholds Broad Hatch-Waxman Venue Options for Innovator Pharmaceutical Companies|
Gregory A. Castanias, Pablo D. Hendler, Matthew J. Hertko, Anthony M. Insogna, Gasper J. LaRosa; Jones Day;
April 12, 2016, previously published on March 2016On March 18, 2016, the United States Court of Appeals for the Federal Circuit issued a combined opinion in Acorda Therapeutics Inc. v. Mylan Pharmaceuticals Inc., No. 2015-1456, and AstraZeneca AB v. Mylan Pharmaceuticals Inc., No. 2015-1460, holding that an Abbreviated New Drug Application...
|Amarin and FDA Agree to Landmark Settlement on Off-Label Promotion|
Michael A. Carvin, Toni-Ann Citera, Colleen Heisey, Karen P. Hewitt, Laura F. Laemmle-Weidenfeld; Jones Day;
April 6, 2016, previously published on March 2016On March 8, 2016, Amarin Pharma, Inc. reached a noteworthy settlement in its lawsuit against the U.S. Food and Drug Administration ("FDA") to protect its First Amendment right to promote the drug Vascepa for nonapproved, off-label uses. Amarin Pharma, Inc. v. FDA (S.D.N.Y. No. 15-cv-3588)...
|California Attorney General Releases Data Breach Report|
Daniel J. McLoon, Michael G. Morgan, Jeffrey Rabkin, David W. Schecter, Gregory P. Silberman; Jones Day;
March 3, 2016, previously published on February 2016On Tuesday, February 16, 2016, the California Attorney General's Office released its Data Breach Report, analyzing the 657 data breaches reported to the Attorney General's office from 2012 to 2015. According to the report, the majority of the reported breaches were the result of security failures....
|Motions to Disqualify Opposing Counsel in Patent Trial and Appeal Board Proceedings|
David B. Cochran, Thomas E. Friebel, Anthony M. Insogna, Matthew W. Johnson, Gregory L. Lippetz; Jones Day;
February 16, 2016, previously published on February 2016Motions to disqualify opposing counsel often raise difficult issues of legal ethics. Behind any motion to disqualify, two competing interests are implicated: the client's right to the attorney of its choice versus the need to maintain ethical standards of professional responsibility. Few things are...
|The EEOC Proposes to Collect Pay Data from Employers on EEO-1s|
Fred W. Alvarez, Richard J. Bergstrom, Terri L. Chase, Eric S. Dreiband, Michael J. Gray; Jones Day;
February 11, 2016, previously published on February 2016On February 1, 2016, the U.S. Equal Employment Opportunity Commission ("EEOC") published in the Federal Register proposed changes to the Employer Information Report ("EEO-1") that would require private employers and federal contractors with 100 or more employees to report...
|FCPA 2015 Year In Review|
Theodore T. Chung, Richard H. Deane, Karen P. Hewitt, Henry Klehm, Hank Bond Walther; Jones Day;
February 9, 2016, previously published on January 2016In 2015, a year after the DOJ resolved several long-term and large-dollar FCPA investigations, the most significant FCPA story was the sharp decrease in both the number and size of the DOJ’s corporate FCPA resolutions. This slowdown may only be a temporary downturn, though, because the DOJ...
|New Partnership Tax Audit Rules Will Impact Private Investment Fund Vehicles|
Peter J. Elias, Olga A. Loy, Teresa A. Maloney, Babak Emil Nikravesh, Patrick B. O'Brien; Jones Day;
December 16, 2015, previously published on November 30, 2015On November 2, 2015, President Barack Obama signed into law the Bipartisan Budget Act of 2015 (the “BBA”). The BBA includes new rules (the “New Audit Rules”) which significantly change many aspects of existing U.S. federal tax law relating to tax audits of entities treated...
|Federal Circuit Refines Patent Damages Analysis as to Apportionment and Standard-Essential Patents|
Keith B. Davis, David M. Maiorana, S. Christian Platt; Jones Day;
December 15, 2015, previously published on December 2015On December 3, 2015, the Federal Circuit vacated a $16 million damages award and remanded for a new determination of a reasonable royalty, agreeing with the district court's apportionment analysis but finding legal error with respect to the court's failure to account for the value due to the patent...